pe
pep-10361 v1 CC-BY-SA-4.0

Experimental blood-sugar peptide (CHEMBL1222092)

A lab-made peptide that switches on the GLP-1 receptor, the same target as Ozempic, to help lower blood sugar and curb appetite. Still experimental, not an approved medicine.

statusbioassayed targetGLP-1R length27 aa refs5
EARLY ENTRY This candidate is newly indexed — supporting evidence is still being added. Have a paper or data point? Contribute below.
status 5 / 5
prediction metrics boltz-2 1.0
ipTM0.887
pTM0.800
avg pLDDT69.9
ranking score0.736
STRUCTURE · PEP-10361 × GLP-1R
ranking0.736
target interface 4.5Å peptide drag rotate · ctrl+scroll zoom · right-click pan
boltz-2 1.0 · mmCIF ↓ download
sequence27 aa
151015202527
QGTFTSDYS KYLDERRAK DFVAWLMNT
in the news 136 articles
details expand to inspect
full evidence table1 metrics
metricvaluetool
EC50 0.087 nM GPCRDB/ChEMBL
3-letter notation
Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Arg-Ala-Lys-Asp-Phe-Val-Ala-Trp-Leu-Met-Asn-Thr
recipeboltz-2 1.0
parametervalue
modelboltz-2 1.0
weights
hardwarenvidia_nim_api
mlx version
python
random seed
msa strategycolabfold_nvidia
diffusion samples1
runtime
predicted bymlx@peptide
predicted at2026-04-25
citationbibtex
peptidemodel (2026). Experimental blood-sugar peptide (CHEMBL1222092) (pep-10361, v1). PeptideModel. https://peptidemodel.com/card/pep-10361
@peptide{pep10361,
  sequence = {QGTFTSDYSKYLDERRAKDFVAWLMNT},
  target   = {glp-1r},
  author   = {peptidemodel},
  year     = {2026},
  status   = {bioassayed}
}
related peptides 5 by signal overlap
clinical trials 0 trials · checked 2026-05-22
0
no registered clinical trials as of 2026-05-22; we'll re-check periodically
references 5 papers
discussion no comments
sign in to comment
peptidemodel.com CC-BY-SA-4.0 research only · not for human use